Equity · Healthcare
NMRA
NASDAQNeumora Therapeutics (NMRA)
The line runs 1.53 USD on 24 August through 0.7469 USD on 17 September, on a scale from 0.5 to 2.0. Days the market did not trade hold the previous close, flat.
- Market cap
- 140.9M USD
- EPS, diluted, year to Dec 2025
- −1.45 USD
- Avg volume
- 98.2K
as of Sep 17, 2026
Have Neumora Therapeutics (NMRA) insiders bought or sold shares recently?
NMRA's newest Form 4 filing is dated 21 August 2026: none in the last 90 days.
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 21 Aug 2026 | Aurora Daljit SinghSee Remarks | Sell | 41,608 | 66K USD |
| 20 Aug 2026 | Aurora Daljit SinghSee Remarks | Sell | 134,452 | 204K USD |
| 19 Aug 2026 | Aurora Daljit SinghSee Remarks | Sell | 61,918 | 102K USD |
| 18 Aug 2026 | Aurora Daljit SinghSee Remarks | Sell | 69,149 | 110K USD |
| 17 Aug 2026 | Aurora Daljit SinghSee Remarks | Sell | 146,706 | 220K USD |
| 17 Feb 2026 | Aurora Daljit SinghSee Remarks | Sell | 6,165 | 22K USD |
| 17 Feb 2026 | BERNS PAUL LSee Remarks | Sell | 9,819 | 34K USD |
| 17 Feb 2026 | Milligan Michael LeeSee Remarks | Sell | 1,436 | 5K USD |
| 17 Feb 2026 | Pinto JoshuaPresident | Sell | 5,967 | 21K USD |
| 11 Nov 2025 | Aurora Daljit SinghSee Remarks | Sell | 114,703 | 307K USD |
| 27 Oct 2025 | ARCH Venture Partners XII, LLC | Buy | 1,915,700 | 5.0M USD |
| 27 Oct 2025 | ARCH Venture Partners X, LLC | Buy | 1,915,700 | 5.0M USD |
| Bought | 3 open-market purchases | 5,747,100 | $15.00M | |
| Sold | 10 open-market sales | 591,923 | $1.09M |
Showing the 12 most recent of 13 open-market trades in this window. The figures above count all of them.
5 other filings: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 21 Aug 2026 | Aurora Daljit SinghSee Remarks | Option exercise | 41,608 | 30K USD |
| 20 Aug 2026 | Aurora Daljit SinghSee Remarks | Option exercise | 134,452 | 97K USD |
| 19 Aug 2026 | Aurora Daljit SinghSee Remarks | Option exercise | 61,918 | 45K USD |
| 18 Aug 2026 | Aurora Daljit SinghSee Remarks | Option exercise | 69,149 | 50K USD |
| 17 Aug 2026 | Aurora Daljit SinghSee Remarks | Option exercise | 112,686 | 81K USD |
Which funds hold Neumora Therapeutics (NMRA)?
7 of the 45 institutional funds we track reported a Neumora Therapeutics position for the quarter ended 30 Sep 2026 — a combined 4.7M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| AQR Capital Management | Added | 3,062,846 | 1.8M USD | +22,399.4% |
| Two Sigma Investments | Trimmed | 1,390,429 | 829K USD | −38.1% |
| Renaissance Technologies | Held (±25%) | 1,129,735 | 674K USD | −10.5% |
| Citadel Advisors | Held (±25%) | 1,027,951 | 613K USD | +24.0% |
| Tudor Investment Corp | Trimmed | 631,091 | 376K USD | −53.5% |
| Marshall Wace | Trimmed | 330,514 | 198K USD | −63.5% |
| Millennium Management | Trimmed | 328,544 | 196K USD | −35.5% |
What has been filed or recorded for Neumora Therapeutics (NMRA)?
The filings we hold for Neumora Therapeutics, newest first: 3 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 16 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 16 Oct 2026 | Fails to deliver | Shares failed to deliver | 88,883 shares | 38K USD notional · 0.047% of shares out |
| 13 Oct 2026 | Fails to deliver | Shares failed to deliver | 429 shares | 189 USD notional · <0.001% of shares out |
| 07 Oct 2026 | Fails to deliver | Shares failed to deliver | 67,361 shares | 32K USD notional · 0.036% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.18 USD | |
| 30 Sep 2026 | Financials | Total assets | 95.0M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 18.6M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.23 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.30 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −1.45 USD | |
| 31 Dec 2025 | Financials | Net income | −236.9M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −1.45 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.35 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.33 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.42 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −1.53 USD |
What do people ask about Neumora Therapeutics (NMRA)?
What did Neumora Therapeutics shares close at?0.7469
Neumora Therapeutics closed at 0.7469 USD on 17 Sep 2026, down 3.01% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Neumora Therapeutics’ market cap?140.9M
Neumora Therapeutics is worth 140.9M USD by market value as of 17 Sep 2026, which is the share price times the shares on issue from its SEC filings.
Have Neumora Therapeutics insiders bought or sold shares recently?
No Neumora Therapeutics insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 21 Aug 2026 (SEC Form 4). See Insiders
Which funds own Neumora Therapeutics?7 of 45
7 of the 45 funds we track reported a Neumora Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were AQR Capital Management, Two Sigma Investments and Renaissance Technologies. See Funds
When did Neumora Therapeutics last report earnings?−0.18
Neumora Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.18 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words